汉森制药(002412) - 2018 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders rose by 97.97% to CNY 25,680,673.16 for the reporting period[7] - Operating income for the period was CNY 233,713,563.26, reflecting a 15.95% increase year-on-year[7] - Basic earnings per share increased by 98.17% to CNY 0.0868[7] - Net profit increased by CNY 20,098,879.80, a growth of 30.33%, driven by an increase in operating income of CNY 66,232,887.30, a year-on-year growth of 11.12%[17] - The company reported a total profit of ¥30,394,071.85, compared to ¥15,461,029.98 in the previous period, indicating an increase of approximately 96.5%[38] - The total profit for the current period was CNY 102,033,584.55, compared to CNY 79,480,945.88 in the previous period, indicating an increase of about 28.4%[46] - The company’s total comprehensive income for the current period was CNY 86,361,859.83, compared to CNY 66,262,980.03 in the previous period, indicating an increase of approximately 30.4%[47] Cash Flow - Net cash flow from operating activities surged by 152.14% to CNY 52,480,462.58[7] - Operating cash flow net increased by CNY 71,124,838.72, a growth of 89.91%, mainly due to a significant increase in cash received from sales of goods and services[17] - Cash and cash equivalents net increase amounted to CNY 46,785,129.22, a growth of 126.37%, attributed to the increase in operating cash flow[18] - The company reported a net cash flow from operating activities of CNY 150,232,152.80, significantly higher than CNY 79,107,314.08 in the previous period, marking an increase of about 89.9%[51] - The cash flow from operating activities totaled ¥643,057,640.25, compared to ¥532,396,763.11 in the previous period, representing a growth of 20.8%[56] Assets and Liabilities - Total assets increased by 5.40% to CNY 1,792,261,064.44 compared to the end of the previous year[7] - Net assets attributable to shareholders grew by 7.08% to CNY 1,305,593,197.50 compared to the end of the previous year[7] - Total liabilities increased slightly to ¥486,667,866.94 from ¥481,178,186.56, a change of about 1.0%[31] - Current assets increased to ¥506,879,459.62 from ¥497,081,297.70, representing a growth of approximately 1.6%[29] - Non-current assets totaled ¥1,285,381,604.82, up from ¥1,203,328,226.53, indicating an increase of about 6.8%[30] Shareholder Information - The company reported a total of 11,551 common shareholders at the end of the reporting period[11] - The largest shareholder, Xinjiang Hansen Equity Investment Management Partnership, holds 42.13% of the shares[11] Research and Development - R&D expenses increased by CNY 8,586,252.40, a growth of 46.22%, due to increased investment in the consistency evaluation of various pharmaceutical products[16] - Research and development expenses rose significantly to ¥9,910,683.19 from ¥5,966,214.01, reflecting a growth of approximately 66.5%[36] - Research and development expenses rose to CNY 23,916,712.43 from CNY 16,516,656.02, showing an increase of approximately 44.7%[49] Investment Income - Investment income increased by CNY 2,997,327.57, a growth of 64.29%, mainly due to increased long-term equity investment income from Hunan Sanxiang Bank[16] - The company reported investment income of CNY 7,659,215.46 from joint ventures and associates, up from CNY 4,661,887.89, representing an increase of approximately 64.3%[49] - Investment income surged to ¥6,577,771.55 from ¥904,371.99, reflecting an increase of approximately 628.5%[38] Operating Costs - Total operating costs amounted to ¥211,225,336.30, up from ¥188,392,769.30, indicating an increase of about 12.9%[36] - Sales expenses increased to ¥118,872,360.21 from ¥105,458,190.01, which is an increase of about 12.8%[36]